Marketed therapeutic antibodies compendium
暂无分享,去创建一个
[1] N. Mahmud,et al. Antibody immunosuppressive therapy in solid-organ transplant: Part I. , 2010, mAbs.
[2] C. Milstein,et al. Expression of spleen cell immunoglobulin phenotype in hybrids with myeloma cell lines , 1981, Somatic cell genetics.
[3] L. Marks. The birth pangs of monoclonal antibody therapeutics , 2012, mAbs.
[4] J. Reichert. Which are the antibodies to watch in 2012? , 2012, mAbs.
[5] N. Mahmud,et al. Antibody immunosuppressive therapy in solid-organ transplant , 2010 .
[6] G. Köhler,et al. A better cell line for making hybridomas secreting specific antibodies , 1978, Nature.
[7] C. Punt,et al. Edrecolomab alone or in combination with fluorouracil and folinic acid in the adjuvant treatment of stage III colon cancer: a randomised study , 2002, The Lancet.
[8] M. S. Ramakrishnan,et al. Nimotuzumab, a promising therapeutic monoclonal for treatment of tumors of epithelial origin , 2009, mAbs.
[9] K. Ohshima,et al. Phase I study of KW-0761, a defucosylated humanized anti-CCR4 antibody, in relapsed patients with adult T-cell leukemia-lymphoma and peripheral T-cell lymphoma. , 2010, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.
[10] Leo T Rosenberg. Delaying approval of a critical drug: Safety, efficacy, economics, compassion , 1994, The Journal of medical humanities.